

EFFECT OF REVERATOL ON CARDIO VASCULAR SYSTEM

Shani Kannaujiya*, Saheb Husain Ansari, Anmol Vikram, Kuldeep Kumar, Vikash, Praveen Kumar, Dileep Yadav, Brijesh Kumar, Mo Alkama Chaudhary, Adarsh Kumar Verma, Gaurav Verma and Dhiraj

R.C.C. College of Pharmacy Basti UP.



*Corresponding Author: Shani Kannaujiya

R.C.C. College of Pharmacy Basti UP.

Article Received on 08/04/2025

Article Revised on 29/04/2025

Article Accepted on 19/05/2025

ABSTRACT


Resveratrol (RESV) is a polyphenolic compound found in various plants, including grapes, berries and peanuts, and its processed foods as red wine. RESV possesses a variety of bioactivities, including antioxidant, anti-inflammatory, cardioprotective, antidiabetic, anticancer, chemopreventive, neuroprotective, renal lipotoxicity preventative, and renal protective effects. The phytoantitoxin resveratrol is a plant-derived polyphenol with phytoestrogenic properties. Resveratrol protects the cardiovascular system by mechanisms that include defense against ischemic-reperfusion injury, promotion of vasorelaxation, protection and maintenance of intact endothelium, anti-atherosclerotic properties, inhibition of low-density lipoprotein oxidation, suppression of platelet aggregation, and estrogen-like actions. The purpose of this article to show the effect of resveratrol on cardiac vascular system.

KEYWORDS: Flavonoids, Resveratrol, Role of Resveratrol in cardioprotective.

INTRODUCTION

Flavonoids are an important class of natural products. They are generally known to be present in plants and plant based products. These include various fruits, vegetables, herbs and beverages such as tea and red wine. Flavonoids are associated with a broad spectrum of health promoting effects. They are an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function.^[1] Flavonols are phytochemical compounds found in high

concentrations in a variety of plant-based foods and beverages. Based on their structure, flavonols are classified as flavonoids and include the following compounds: quercetin, kaempferol, and myricetin. The specific amounts of flavonols in foods are affected by a range of factors including plant type and growth, season, light, degree of ripeness, food preparation, and processing. Despite these variables, high concentrations of flavonols can be found in apples, apricots, beans, broad beans, broccoli, cherry tomatoes, chives, cranberries, kale, leeks, pear, onions, red grapes, sweet cherries, and white currants.^[2]






Figure 1: classification of flavonoids,sub sources,sources of flavonoids and benefits.

1.1 Resveratrol

Resveratrol is a metabolite produced in more than 70 plant species in response to environmental stress such as mechanical injury, microbial infection, and UV irradiation. Found in high concentrations in red grapes and their derivatives, which was first isolated in 1940. Resveratrol exists in nature in two isomeric forms (Figure 2): *trans*-resveratrol and *cis*-resveratrol. Two phenol rings are linked by a styrene double bond to generate (3,5,4'-trihydroxy-*trans*-stilbene) is a stilbenoid, a type of natural phenol, and a phytoalexin produced naturally by several plants in response to injury or when the plant is under attack by pathogens such as bacteria or fungi.^[3] Food sources of resveratrol

include the skin of grapes, blueberries, raspberries, and mulberries.^[4] Resveratrol was first isolated from the roots of white hellebore in 1940 and later, in 1963, from the roots of *Polygonum cuspidatum* used in both Chinese and Japanese medicines. It was initially characterized as a phytoalexin but gained considerable attention when it was postulated to explain some of the cardioprotective effects of red wine.^[5] Red wine is the most common source of resveratrol, with concentrations of up to 14 mg L⁻¹, but its concentration varies between and within each type of grapes used. White wines generally have concentrations less than 0.1 mg L⁻¹.^[6,7] Resveratrol is also reported to be present in peanuts, soys and other plant products although the amount is almost negligible

compared to that in wines.^[6,8] A number of resveratrol supplements have been developed, with capsules containing anywhere from 1 mg through to as much as 1g per dose. Recently trans resveratrol has also been found in dark chocolate.^[9] There are two isoforms of resveratrol: cis- and trans- resveratrol. Trans-resveratrol is biologically active isoform. The main source of

resveratrol is grape skin. Also, resveratrol is present in fruits such as cranberry, lingonberry, bilberry, mulberry, deer berry, blueberry, sparkleberry, partridgeberry, jackfruit, and in a peanut orchid tree, scots pine, corn lily, white hellebore, eucalyptus, spruce etc.^[10,11] Resveratrol has anti-cancer and anti-inflammatory effects and beneficial cardiovascular effects.^[11]




Figure 2: Trans-resveratrol, Cis- resveratrol.

1.2. Bioavailability of resveratrol

After oral administration, resveratrol absorbs rapidly (75%) by transepithelial diffusion. It is detected in a 15-min post-administration and reaches peak concentrations after 30 min. Values returned to baseline within 4 h.^[12] Previously, we showed that different bile acids micellar solutions improved resveratrol solubilization.^[13] The metabolism of resveratrol is extensive in the intestine and liver. Because of intense metabolism, an oral bioavailability of resveratrol is less than 1%. The major active metabolites of resveratrol are glucuronides (trans-resveratrol-3-O-glucuronide) and sulfates (transresveratrol-3-sulfate). Also, colonic bacterial metabolism plays an important role in resveratrol metabolism.^[14]

2. Resveratrol used as Cardioprotective

It has long been known that moderate drinking of red wine reduces the risk of heart disease.^[15] Studies suggest that resveratrol in red wine may play an important role in this phenomenon.^[16]

- It achieves the effects by the following functions.^[17]
1. Inhibition of vascular cell adhesion molecule expression;
 2. Inhibition of vascular smooth muscle cell proliferation;
 3. Stimulation of endothelial nitric oxide synthase (eNOS) Activity;
 4. Inhibition of platelet aggregation;
 5. Inhibition of LDL peroxidation; The cardioprotective effects of resveratrol are also theorized to be a form of preconditioning—the best method of cardioprotection, rather than direct therapy

2.1. Some Proposed Mechanisms of Action of Resveratrol in rats that May Decrease Cardiovascular Disease in Humans

S. No.	Cardiovascular disease	Mechanism of action of resveratrol
1.	Coronary heart disease and myocardial infarction	Cardiac preconditioning including reducing reactive oxygen species, improving vasorelaxation and angiogenesis, activation of adenosine A1 and A3 receptors, which then transmit survival signals via PI3-kinase-Akt-Bcl-2, increasing heme oxygenase-1 expression, activation of sirtuins, preventing inflammation and apoptosis, preventing platelet aggregation, inhibition of cardiac fibroblast proliferation and differentiation, delaying atherosclerosis as well as decreasing cardiovascular remodeling. ^[18,19,20,21,22,23]
2.	Cardiac arrhythmias	Reduction of the duration of arrhythmia and incidence of ventricular tachycardia, along with enhanced action potential duration (APD). ^[24,25]
3.	Hypertension	Activation of sirtuins, increased production of NO and decreased superoxide concentrations, reduced Ca ²⁺ uptake into vascular smooth muscle cells. ^[26,27,28]
4.	Atherosclerosis	Delay at multiple levels such as cellular signalling, enzymatic pathways, apoptosis and gene expression. ^[29]

2.2. Cardiac Preconditioning with Resveratrol

Preconditioning describes the development of resistance to injury to the heart caused by extended ischaemia and reperfusion.^[30] Physiological mechanisms include short periods of ischaemia followed by reperfusion but the therapeutic potential lies in the possibility that pharmacological agents will selectively induce preconditioning. Resveratrol may imitate this process of preconditioning, providing a pharmacological stimulus to reduce heart damage from ischaemia.^[31, 32, 33]

2.3. Vascular Remodelling as a Target for Resveratrol

As in the heart, activation of SIRT1 may initiate the vascular actions of resveratrol. SIRT1 is important as a key regulator of vascular endothelial homeostasis controlling angiogenesis, vascular tone and endothelial dysfunction.^[34, 35]

2.4. Cardiac Remodelling as a Target for Resveratrol

The heart responds with remodelling during chronic cardiovascular disease such as hypertension, heart failure or myocardial infarction. The remodelling process involves hypertrophy of myocytes, hyperplasia of fibroblasts and vascular smooth muscle cells, excessive collagen deposition and conduction abnormalities.^[36, 33]

CONCLUSION

The therapeutic use of a dietary component such as resveratrol in humans requires evidence of clinical effectiveness. This requires an assessment of an effective dose of the active drug at the target tissue to identify suitable nutritional or therapeutic doses without toxicity. Continuing studies on the mechanisms of action of resveratrol at a molecular level are necessary to define therapeutic potential. Rodent models of human cardiovascular disease have shown that resveratrol improves cardiovascular structure and function within the context of a wide range of cardiovascular conditions.

REFERENCES

1. Manach C et al. *Am J Clin Nutr*, 2004; 79(5): 727-747.
2. Aherne SA et al. Dietary flavonols: chemistry, food content, and metabolism. *Nutrition*, 2002; 18: 75-81.
3. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol. A conundrum. *Cancer Epidemiol Biomarkers Prev*, 2003; 12: 953-957.
4. Goldberg DM et al. Direct injection gas chromatographic mass spectrometric assay for trans-resveratrol. *Anal Chem*, 1994; 66: 3959-3963.
5. Frankel EN et al. Inhibition of human LDL oxidation by resveratrol. *Lancet*, 1993; 341: 1103-1104.
6. Burns J et al. Plant foods and herbal sources of resveratrol. *J. Agric. Food Chem*, 2012; 50: 3337-3340.
7. Fermont L. Biological effects of resveratrol. *Life Sci*, 2000; 66: 663-73.
8. Bolivar M et al. Production and secretion of resveratrol in hairy root cultures of peanut. *Phytochemistry*, 2007; 68: 1992-2003.
9. Counet C et al. Chocolate and cocoa: New sources of transresveratrol and trans-piceid. *Food Chem*, 2006; 98: 649-657.
10. Dudley J et al. Resveratrol a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. *J Nutr Biochem*, 2009; 20(6): 443-452.
11. Mukherjee S et al. Dose-dependency of resveratrol in providing health benefits. *Dose Response*, 2010; 8(4): 478-500.
12. Soleas GJ et al. Absorption of trans-resveratrol in rats. *Methods Enzymol*, 2001; 335: 145-154.
13. Atanacković M et al. Solubilization of resveratrol in micellar solutions of different bile acids. *Colloids Surf B Biointerfaces*, 2009; 72(1): 148-154.
14. Walle T. Bioavailability of resveratrol. *Ann N Y Acad Sci*, 2011; 1215: 1223.
15. Kopp P. Resveratrol, a Phytoestrogen Found in Red Wine. A Possible Explanation for the Conundrum of the 'French paradox. *European Journal of Endocrinology*, 1998; 619-620.
16. Asensi M et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. *Free Radic. Biol. Med*, 2002; 33(3): 387-98.
17. Raventos L et al. Direct HPLC Analysis of cis- and trans-Resveratrol and Piceid Isomers in Spanish Red Vitis vinifera Wines. *J. Agric. Food Chem*, 1995; 43(4): 281-283.
18. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. *Nat. Rev. Drug. Discov*, 2006; 5: 493-506.
19. Das S, Das DK. Resveratrol a therapeutic promise for cardiovascular disease. *Recent Pat. Cardiovasc. Drug. Discov*, 2007; 2: 133-138.
20. Pervaiz S et al. Resveratrol: its biologic targets and functional activity. *Antioxid. Redox. Signal*, 2009; 11: 2851-2897.
21. Das S et al. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption. A potential mechanism for resveratrol preconditioning of the heart. *Vasc Pharmacol*, 2005; 42: 281-289.
22. Maulik N, Das DK. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. *Biochim. Biophys. Acta*, 2008; 1780: 1368-1382.
23. Maulik N. Reactive oxygen species drives myocardial angiogenesis? *Antioxid. Redox. Signal*, 2006; 8: 2161-2168.
24. Chen et al. In vivo electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. *Eur. J. Pharmacol*, 2007; 554: 196-204.
25. Chen YR et al. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. *Cardiovasc. Drugs. Ther*, 2008; 22: 479-485.
26. Calderone V et al. Functional contribution of the endothelial component to the vasorelaxing effect of

- resveratrol and NS 1619, activators of the large-conductance calcium-activated potassium channels. *Naunyn. Schmiedeberg's Arch. Pharmacol*, 2007; 375: 73-80.
27. Bukarica G et al. A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. *J. Pharmacol. Sci*, 2008; 108: 124-130.
28. Buluc M et al. Resveratrol decreases calcium sensitivity of vascular smooth muscle and enhances cytosolic calcium increase in endothelium. *Vasc. Pharmacol*, 2006; 44: 231-237.
29. Delmas D et al. Resveratrol: preventing properties against vascular alterations and ageing. *Mol. Nutr. Food Res*, 2005; 49: 377-395.
30. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. *Am. J. Physiol. Heart Circ. Physiol*, 2007; 292: 19-27.
31. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. *Mol. Interv*, 2006; 6: 36-47.
32. Das S, Das DK. Resveratrol a therapeutic promise for cardiovascular disease. *Recent Pat. Cardiovasc. Drug. Discov*, 2007; 2: 133-138.
33. Paul A et al, The Cardiovascular Nutraceuticals of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential. *Current Medicinal Chemistry*, 2010; 17: 2442-2455.
34. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. *Cell Cycle*, 2008; 7: 2117-2122.
35. Miyazaki R et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. *Arterioscler. Thromb. Vasc Biol*, 2008; 28: 1263-1269.
36. Chan AY et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. *J. Biol. Chem*, 2008; 283: 24194-24201.